Jacobs Levy Equity Management’s Biolase BIOL Stock Holding History
Bought
Maintained
Sold
Other funds holding BIOL
TMC
Jacobs Levy Equity Management's BIOL Position: Q2 2017 in Review
Jacobs Levy Equity Management sold out of Biolase (BIOL) in Q2 2017, closing a stake of 1 share — an estimated $23K sold.
Jacobs Levy Equity Management first reported a position in BIOL in Q2 2016 and held it in 2 quarters. The position peaked at $23K in Q1 2017. 32 funds tracked by Wall St. Rank hold BIOL as of Q2 2017.
- Jacobs Levy Equity Management reported no remaining Biolase position as of Q2 2017 after selling out during the quarter.
- Jacobs Levy Equity Management sold 1 Biolase share in Q2 2017, an estimated $23K.
- Jacobs Levy Equity Management first reported a position in Biolase in Q2 2016 and held it in 2 quarters.
- Jacobs Levy Equity Management's Biolase position peaked at $23K in Q1 2017.
- 32 funds tracked by Wall St. Rank held Biolase as of Q2 2017.
Based on Jacobs Levy Equity Management's 13F filing for Q2 2017, filed 14 Aug 2017.